Objective: To analyze the clinical-biological features and outcomes of patients with mantle cell lymphoma (MCL).
Methods: The clinical and laboratory data of 104 patients with newly diagnosed MCL who were admitted to the Department of Hematology, Fujian Medical University Union Hospital from January 2011 to December 2019 were retrospectively analyzed, and the efficacy was observed through survival analysis.
Results: Among 104 MCL patients, 88 were male and 16 were female. The median age was 54 (25-79) years old, 93.0% (93/100) of the patients with advanced stage (III and IV stages) and 48.08% (50/104) of the patients with bone marrow infiltration. Patients with Ki-67≥50% had higher WBC counts and LDH levels. Univariate analysis showed that the patients with WBC≥15×109/L, bone marrow involvement, high LDH, high β2-MG levels, Ki-67≥50%, SOX11-, had lower OS and EFS rates (P =0.005, 0.049, 0.033, 0.025, 0.042, 0.018 and 0.001, 0.021, 0.024, 0.035, 0.014, 0.026). The OS rate and EFS rate of patients in R-CHOP and R-Hyper-CVAD treatment groups were significantly higher than those in other treatment groups (P =0.02, 0.002 and P =0.001, 0.001). Patients with autologous stem cell transplantation (ASCT) had higher OS rate and EFS rate (P =0.037, 0.013). Multivariate COX analysis showed that only WBC count, SOX11 expression and whether achieved CR after 4 courses treatment were the independent factors affecting the prognosis.
Conclusion: MCL mainly occur in elderly men. There are many factors affecting patients' survival, while WBC≥15×109/L, negative expression of SOX11 and failure to achieve CR after 4 courses of treatment are adverse factors for MCL patients.
题目: 套细胞淋巴瘤患者的生物学特征及预后.
目的: 分析套细胞淋巴瘤（MCL）患者的生物学特征并初步探讨其预后。.
方法: 回顾性分析2011年1月至2019年12月福建医科大学附属协和医院血液科收治的104例MCL患者的临床及实验室资料，并通过生存分析来观察疗效。.
结果: 104例患者中男性88例，女性16例，中位年龄54（25-79）岁，晚期（Ⅲ和Ⅳ期）患者占93.0％（93/100），伴有骨髓浸润的占48.08％（50/104）。Ki-67≥50%的患者具有较高的WBC数和LDH水平。单因素分析结果显示，发病时WBC≥15×109/L、累及骨髓、高LDH、高β2-微球蛋白水平、Ki-67≥50%、SOX11-患者的OS率和EFS率更低 （P =0.005，0.049，0.033，0.025，0.042，0.018和0.001，0.021，0.024，0.035，0.014，0.026），R-CHOP和R-Hyper-CVAD治疗组的患者2年OS率和EFS率明显高于其他治疗组（P =0.02，0.002和P =0.001，0.001），联合自体干细胞移植的患者具有更高的OS率和EFS率（P =0.037，0.013）。多因素COX分析结果显示，仅WBC数、SOX11是否表达以及4个疗程能否达到缓解是影响患者预后的因素。.
结论: MCL患者以老年男性多见，影响预后的因素较多，而WBC数≥15×109/L、SOX11-以及4个疗程未能达到缓解是影响患者预后的不利因素。.
Keywords: immunohistochemistry; mantle cell lymphoma; prognosis.